Safety of Infliximab: Primum non nocere
Open Access
- 1 July 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 10 (4), 486-487
- https://doi.org/10.1097/00054725-200407000-00028
Abstract
The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Gastroenterology. 2004;126:19–31.Keywords
This publication has 8 references indexed in Scilit:
- Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trialGastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Tuberculosis and Treatment with InfliximabNew England Journal of Medicine, 2002
- Exacerbation of mycobacterium tuberculosis enteritis masquerading as crohn’s disease after treatment with a tumor necrosis factor-α inhibitorAmerican Journal Of Medicine, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Infliximab Approved for Use in Crohnʼs Disease: A Report on the FDA GI Advisory Committee ConferenceInflammatory Bowel Diseases, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997